Tiziana Triulzi

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 60 publications

Melanoma stem cells drive macrophage reprogramming to a hybrid phenotype, modulating melanoma stemness and compromising NK cell-mediated immunity.

Melanoma stem cells drive macrophage reprogramming to a hybrid phenotype, modulating melanoma stemness and compromising NK cell-mediated immunity.

Journal: Frontiers in immunology

Published: September 03, 2025

Correction: CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer.

Correction: CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: May 29, 2025

Proteomic landscape of decellularized breast carcinomas identifies C-type lectin domain family 3 member A as a driver of cancer aggressiveness.

Proteomic landscape of decellularized breast carcinomas identifies C-type lectin domain family 3 member A as a driver of cancer aggressiveness.

Journal: NPJ breast cancer

Published: October 02, 2024

Axillary surgery versus no-axillary staging in T1N0 breast cancer: 20-year follow-up of the INT 09/98 randomized clinical trial.

Axillary surgery versus no-axillary staging in T1N0 breast cancer: 20-year follow-up of the INT 09/98 randomized clinical trial.

Journal: The British journal of surgery

Published: July 17, 2024

CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer.

CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: March 27, 2024

Impact of in vitro SARS-CoV-2 infection on breast cancer cells.

Impact of in vitro SARS-CoV-2 infection on breast cancer cells.

Journal: Scientific reports

Published: July 23, 2023

The Emerging Role of the Microbiota in Breast Cancer Progression.

The Emerging Role of the Microbiota in Breast Cancer Progression.

Journal: Cells

Published: June 23, 2023

PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis.

PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis.

Journal: Journal for immunotherapy of cancer

Published: April 09, 2023

A three-gene signature marks the time to locoregional recurrence in luminal-like breast cancer.

A three-gene signature marks the time to locoregional recurrence in luminal-like breast cancer.

Journal: ESMO open

Published: February 03, 2023

SAA1-dependent reprogramming of adipocytes by tumor cells is associated with triple negative breast cancer aggressiveness.

SAA1-dependent reprogramming of adipocytes by tumor cells is associated with triple negative breast cancer aggressiveness.

Journal: International journal of cancer

Published: January 30, 2023

HER2 mRNA Levels, Estrogen Receptor Activity and Susceptibility to Trastuzumab in Primary Breast Cancer.

HER2 mRNA Levels, Estrogen Receptor Activity and Susceptibility to Trastuzumab in Primary Breast Cancer.

Journal: Cancers

Published: October 28, 2022

The EU-funded I3LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy.

The EU-funded I3LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy.

Journal: Clinical lung cancer

Published: September 29, 2022

Showing 1-12 of 60

Last Updated: 09/26/2026